Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TB

- PMLiVE

J&J begins search for a coronavirus vaccine as confirmed cases rise

Death toll has now reached 170, with 7,711 confirmed cases in China

- PMLiVE

GSK licenses its tuberculosis vaccine to Gates MRI

Vaccine has demonstrated around 50% efficacy in preventing disease

- PMLiVE

New coronavirus sees drug developers scramble to develop a vaccine

Researchers work to combat emerging threat

- PMLiVE

GSK’s pivotal TB vaccine could prevent millions of deaths

Key study took place in TB-endemic regions, testing 3,500 participants

- PMLiVE

J&J pledges $500m investment into HIV and tuberculosis R&D

Aims to help eliminate both diseases by 2030

- PMLiVE

J&J expands its TB research programme

Partners with Indian groups CSIR and IMTECH to develop new treatments

EU flag

EU launches HIV action plan

Aims to "significantly contribute" to elimination of HIV in EU by 2020

- PMLiVE

Europe’s health information systems to be modernised

Joint EC-WHO work will form a major strand of their renewedcollaboration

- PMLiVE

Study shows Otsuka’s TB drug works even in worst cases

Deltybaeffective even in cases that are unlikely to respond to any other drug

Sanofi reception

Sanofi’s Priftin cleared for latent tuberculosis in the US

FDA approves Priftin with isoniazid for patients aged two years and older

- PMLiVE

Researchers develop breath test for TB

Inhaled form of isoniazid could show almost instant results

Novartis building

Novartis licenses tuberculosis R&D to TB Alliance

Includes drugs to tackle resistant forms of the disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links